IRWD vs PHAT
IRWD: Ironwood Pharmaceuticals is a GI-focused biotech company that generates stable profits from its blockbuster IBS-C therapy, LINZESS, while developing a pipeline for rare intestinal diseases. PHAT: Phathom Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative treatments for gastrointestinal diseases, anchored by its potassium-competitive acid blocker platform.
Side-by-side fundamentals
| Metric | IRWD | PHAT | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $4.23 | $8.75 | |
| Market cap as of 2026-08-03 | $696M | $708M | |
| P/E as of 2026-08-03 | 7.23 | n/a | |
| Net margin as of 2026-08-03 | +28.3% | -76.8% | IRWD higher |
| Gross margin as of 2026-08-03 | +100.0% | +84.9% | IRWD higher |
| Operating margin as of 2026-08-03 | +55.4% | -47.5% | IRWD higher |
| ROE as of 2026-08-03 | +29.3% | -232.8% | IRWD higher |
| ROA as of 2026-08-03 | +26.0% | -59.7% | IRWD higher |
| Debt / equity as of 2026-08-03 | 0.56 | 12.38 | IRWD lower |
| Revenue growth (YoY) as of 2026-08-03 | +13.8% | +150.3% | PHAT higher |
| Revenue CAGR (3y) SEC XBRL | -10.3% | n/a | |
| Beta as of 2026-08-03 | 1.11 | 1.11 | |
| 1-year return as of 2026-07-31 close | +456.6% | +2.5% | IRWD higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.